Handok’s Amaryl M exposed to fierce competition

A blockbuster drug in Korea will not be as stable as before with a growing number of pharmaceutical companies poising to enter a 20 billion Amaryl M (glimepiride + metroformin HCl) market.

More than 20 pharmaceutical manufacturers are expected to release the first version of Amaryl M, one of Handok’s flagship products for treatment of type 2 diabetes mellitus, as the re-examination period o...